Core Viewpoint - Dongpeng Holdings is a leading player in the domestic ceramic tile industry, focusing on the research, production, and sales of ceramic products, with a full industry chain advantage [1] Group 1: Business Performance - In Q3 2025, Dongpeng Holdings reported revenue of 4.501 billion, ranking 2nd in the industry, with Marco Polo leading at 4.938 billion [2] - The main business composition includes glazed tiles at 2.457 billion (83.73%), sanitary ceramics at 200 million (6.81%), and bathroom products at 172 million (5.86%) [2] - The net profit for the same period was 349 million, also ranking 2nd, with Marco Polo at 1.062 billion [2] Group 2: Financial Ratios - As of Q3 2025, the asset-liability ratio for Dongpeng Holdings was 33.74%, down from 36.29% year-on-year, lower than the industry average of 39.52% [3] - The gross profit margin was 31.10%, slightly down from 31.23% year-on-year, but still above the industry average of 23.08% [3] Group 3: Executive Compensation - Chairman He Xinming's compensation for 2024 was 2.4324 million, a decrease of 504,900 from 2023 [4] - General Manager He Ying's compensation for 2024 was 2.3079 million, down by 596,300 from 2023 [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 0.23% to 27,800 [5] - The average number of circulating A-shares held per shareholder decreased by 0.23% to 41,100 [5] Group 5: Business Highlights - Despite a 3.9% year-on-year decline in revenue, the net profit increased by 13.1% [5] - The retail channel for ceramic tiles saw an 8.03% increase in revenue, with a 14.96% increase in sales area [5] - The company maintained stable profit margins and strong cash flow, with a cash flow from operations of 651 million, an increase of 162 million year-on-year [6]

Core Viewpoint - Zhongkong Technology's stock price has shown fluctuations, with a year-to-date increase of 7.16% but a recent decline in the last five and twenty trading days [2] Company Overview - Zhongkong Technology Co., Ltd. is based in Hangzhou, Zhejiang Province, established on December 7, 1999, and listed on November 24, 2020 [2] - The company specializes in providing automation control systems and intelligent manufacturing solutions primarily for process industries, enhancing users' automation, digitalization, and intelligence levels [2] - The revenue composition includes: Industrial Automation and Intelligent Manufacturing Solutions (58.43%), Instruments and Meters (17.66%), S2B Business (10.80%), Industrial Software (7.62%), Operation and Maintenance Services (4.43%), and Others (1.06%) [2] Financial Performance - For the period from January to September 2025, Zhongkong Technology reported revenue of 5.654 billion yuan, a year-on-year decrease of 10.78%, and a net profit attributable to shareholders of 432 million yuan, down 39.78% year-on-year [2] - The company has distributed a total of 1.822 billion yuan in dividends since its A-share listing, with 1.516 billion yuan distributed over the past three years [3] Shareholder Structure - As of September 30, 2025, the number of shareholders increased by 9.67% to 43,800, with an average of 17,893 circulating shares per person, a decrease of 8.75% [2] - Major shareholders include E Fund's SSE STAR 50 ETF, which holds 22.8614 million shares, and has decreased its holdings by 3.3223 million shares [3]

Core Viewpoint - Fangsheng Pharmaceutical's stock has experienced fluctuations, with a year-to-date increase of 23.28% and a recent decline of 2.06% on October 30, 2023, indicating market volatility and investor sentiment [1][2]. Financial Performance - For the period from January to September 2025, Fangsheng Pharmaceutical reported a revenue of 1.253 billion yuan, a year-on-year decrease of 7.02%, while the net profit attributable to shareholders increased by 17.60% to 268 million yuan [2]. - Cumulatively, the company has distributed 689 million yuan in dividends since its A-share listing, with 444 million yuan distributed over the past three years [3]. Shareholder Structure - As of September 30, 2025, the number of shareholders decreased by 6.50% to 31,000, while the average circulating shares per person increased by 6.96% to 14,167 shares [2]. - Notable changes in institutional holdings include the entry of new shareholders such as Rongtong China Wind No. 1 Flexible Allocation Mixed Fund and Changxin Jinli Trend Mixed Fund, while previous major shareholders like Industrial Bank Medical Care Stock have exited the top ten [3]. Market Activity - On October 30, 2023, Fangsheng Pharmaceutical's stock price was 12.34 yuan per share, with a trading volume of 66.89 million yuan and a turnover rate of 1.23%, reflecting active market participation [1]. - The stock has seen a net outflow of 6.5856 million yuan from major funds, indicating a cautious approach from institutional investors [1].

Core Points - The stock price of Yirui Technology has decreased by 2.02% to 113.24 CNY per share as of October 30, with a market capitalization of 23.94 billion CNY [1] - The company has seen a year-to-date stock price increase of 67.58%, but has experienced a decline of 1.50% over the last five trading days and 3.06% over the last twenty days [1] - Yirui Technology's main business involves the research, production, sales, and service of digital X-ray detectors, with 81.21% of revenue coming from detector sales [1] Financial Performance - For the period from January to September 2025, Yirui Technology achieved a revenue of 1.549 billion CNY, representing a year-on-year growth of 14.22%, and a net profit attributable to shareholders of 471 million CNY, up 20.61% year-on-year [2] - The company has distributed a total of 789 million CNY in dividends since its A-share listing, with 557 million CNY distributed over the past three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders for Yirui Technology increased by 14.61% to 8,011, while the average circulating shares per person decreased by 12.74% to 24,992 shares [2] - Hong Kong Central Clearing Limited is now the ninth largest circulating shareholder, holding 3.802 million shares as a new shareholder, while Huabao Zhongzheng Medical ETF has exited the top ten circulating shareholders [3]

Core Insights - Zhongwang Software's stock price increased by 2.01% on October 30, reaching 78.85 CNY per share, with a total market capitalization of 13.372 billion CNY [1] - The company has seen a year-to-date stock price increase of 29.57%, with a recent decline of 1.17% over the last five trading days [1] Financial Performance - For the period from January to September 2025, Zhongwang Software reported a revenue of 538 million CNY, representing a year-on-year growth of 4.99%, while the net profit attributable to shareholders was a loss of 40.8487 million CNY, a decrease of 479.34% compared to the previous year [2] - The company has distributed a total of 263 million CNY in dividends since its A-share listing, with 158 million CNY distributed over the last three years [3] Shareholder Information - As of September 30, 2025, Zhongwang Software had 10,300 shareholders, an increase of 34.52% from the previous period, with an average of 16,434 shares held per shareholder, a decrease of 25.66% [2] - The top three circulating shareholders include Wan Jia You Xuan, holding 4 million shares, and Xing Quan He Run Mixed A, holding 2.9786 million shares, with no changes in their holdings [3]

Core Points - The stock price of New Dazheng has decreased by 2.00% to 12.25 CNY per share as of October 30, with a market capitalization of 2.772 billion CNY [1] - Year-to-date, New Dazheng's stock price has increased by 37.22%, but it has seen a decline of 4.30% in the last five trading days [2] - The company reported a revenue of 2.272 billion CNY for the first nine months of 2025, a year-on-year decrease of 11.82%, and a net profit of 104 million CNY, down 2.97% year-on-year [2] Financial Performance - New Dazheng's main business revenue composition includes: basic services 87.79%, urban services 8.22%, innovative services 3.86%, and others 0.13% [2] - The company has distributed a total of 381 million CNY in dividends since its A-share listing, with 197 million CNY distributed in the last three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders for New Dazheng increased by 6.68% to 15,200, while the average circulating shares per person decreased by 6.26% to 14,059 shares [2] - The seventh largest circulating shareholder is Dongfanghong Yuanjian Value Mixed A, holding 2.8237 million shares, an increase of 90,100 shares from the previous period [3]

Core Viewpoint - Furi Group Co., Ltd. has experienced fluctuations in stock price and trading volume, with a notable increase in stock price year-to-date, but recent declines in the short term [1][2]. Stock Performance - The stock price of Furi Group has increased by 22.42% year-to-date, but has decreased by 5.53% in the last five trading days [2]. - Over the past 20 days, the stock price has risen by 20.54%, and over the past 60 days, it has increased by 17.61% [2]. Trading Activity - As of October 30, the stock was trading at 5.81 CNY per share, with a total market capitalization of 5.5 billion CNY [1]. - The net outflow of main funds was 1.41 million CNY, with large orders showing a buy of 31.22 million CNY and a sell of 34.70 million CNY [1]. Company Overview - Furi Group, established on August 11, 1999, and listed on November 24, 2006, is located in Weifang, Shandong Province [2]. - The company primarily produces and sells towel series products (62.86% of revenue), with other segments including decorative fabrics, thermal power products, bedding, chemical products, coating materials, and motors [2]. Financial Performance - For the period from January to September 2025, Furi Group reported a revenue of 3.841 billion CNY, a decrease of 4.45% year-on-year, and a net profit attributable to shareholders of 296 million CNY, down 12.05% year-on-year [3]. - The number of shareholders as of September 30 was 42,700, a decrease of 5.98% from the previous period [3]. Dividend Information - Since its A-share listing, Furi Group has distributed a total of 1.969 billion CNY in dividends, with 331 million CNY distributed over the past three years [4].

Core Viewpoint - The stock price of Shuoshi Biotechnology has experienced significant fluctuations, with a year-to-date increase of 84.68%, but recent trading shows a decline of 2.01% on October 30, 2023, indicating potential volatility in investor sentiment [1][2]. Company Overview - Shuoshi Biotechnology, established on April 12, 2010, and listed on December 5, 2019, is located in Taizhou, Jiangsu Province. The company specializes in the research, production, and sales of in vitro diagnostic reagents and related testing instruments [2]. - The main revenue sources for the company include diagnostic reagents (85.89%), purchased instruments and materials (7.19%), testing instruments (3.84%), testing services (2.24%), and others (0.84%) [2]. Financial Performance - For the period from January to September 2025, Shuoshi Biotechnology reported a revenue of 258 million yuan, reflecting a year-on-year decrease of 3.95%. The net profit attributable to the parent company was 3.15 million yuan, down 88.38% year-on-year [3]. - The company has distributed a total of 1.37 billion yuan in dividends since its A-share listing, with 285 million yuan distributed over the past three years [4]. Shareholder and Market Activity - As of October 20, 2023, the number of shareholders for Shuoshi Biotechnology was 7,620, a decrease of 0.94% from the previous period. The average circulating shares per person increased by 0.94% to 11,006 shares [3]. - The company has appeared on the "Dragon and Tiger List" once this year, with a net purchase of 19.78 million yuan on February 17, 2023, accounting for 26.20% of the total trading volume [2]. Market Sentiment and Trading Activity - On October 30, 2023, the stock price was reported at 75.73 yuan per share, with a trading volume of 45.34 million yuan and a turnover rate of 0.71%. The total market capitalization stood at 6.352 billion yuan [1]. - The net outflow of main funds was 3.40 million yuan, with large orders showing a buy of 12.05 million yuan (26.58%) and a sell of 15.78 million yuan (34.80%) [1].

Core Viewpoint - 康普顿 is a well-established manufacturer of lubricants and automotive chemicals in China, with strong R&D and production capabilities, and its product quality is competitive in the industry [1] Group 1: Business Performance - In Q3 2025, 康普顿 reported revenue of 753 million yuan, ranking 12th among 14 companies in the industry, while the industry leader, 桐昆股份, had revenue of 67.397 billion yuan [2] - The main business composition includes: automotive lubricants at 446.5 million yuan (44.57%), exhaust treatment liquids at 446 million yuan (42.78%), industrial lubricants at 94.4185 million yuan (9.05%), antifreeze at 36.848 million yuan (3.53%), and others at 745,300 yuan (0.07%) [2] - The net profit for the same period was 59.7746 million yuan, ranking 3rd in the industry, with the industry leader's net profit at 1.562 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, 康普顿's debt-to-asset ratio was 12.34%, down from 15.81% year-on-year, significantly lower than the industry average of 46.91% [3] - The gross profit margin for Q3 2025 was 21.17%, an increase from 19.62% year-on-year, and higher than the industry average of 6.71% [3] Group 3: Executive Compensation - The chairman, 朱磊, received a salary of 871,400 yuan in 2024, a decrease of 317,400 yuan from 2023 [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 14.15% to 11,700, while the average number of circulating A-shares held per account increased by 16.49% to 22,000 [5]

Core Viewpoint - Xiangshan Co., Ltd. has experienced a decline in stock price recently, with a year-to-date increase of 19.87% and a notable drop of 8.09% over the past five trading days [1] Financial Performance - As of September 30, 2025, Xiangshan Co., Ltd. reported a revenue of 4.47 billion yuan, reflecting a year-on-year growth of 1.54%. However, the net profit attributable to shareholders decreased by 27.71% to 90.54 million yuan [2] - The company has distributed a total of 128 million yuan in dividends since its A-share listing, with 46.23 million yuan distributed over the past three years [3] Shareholder Information - The number of shareholders as of September 30, 2025, is 13,100, a decrease of 9.44% from the previous period. The average number of circulating shares per person increased by 10.42% to 9,870 shares [2] - Among the top ten circulating shareholders, the fourth largest is the Fuguo Optimized Enhanced Bond C fund, holding 2.92 million shares, an increase of 825,000 shares from the previous period. The eighth largest is the Fuguo Jiuli Stable Allocation Mixed A fund, which is a new shareholder holding 1.10 million shares [3] Business Overview - Xiangshan Co., Ltd. specializes in the research, production, and sales of mid-to-high-end household and commercial weighing instruments, health and sports measurement products, and automotive components. The revenue composition includes 66.31% from automotive smart cockpit components, 18.47% from new energy vehicle parts and charging services, 14.53% from weighing instruments, and 0.69% from other sources [1]